Pitt Street Research sees strong upside in Prescient Therapeutics as one of the most advanced oncology companies on the ASX .

The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...